Measurement of Endothelial Function and Cardiac Output: New Methods

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

101 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-08-31

Study Completion Date

2015-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to analyse test-retest-reliability of functional quantification of endothelial dysfunction through puls-amplitude-tonometry in patients with heart failure with preserved/reduced ejection fraction, pulmonary hypertension, arterial hypertension and diabetic nephropathy. In the same group, test-retest-reliability of circulating endothelial cells as well as test-retest reliability of non invasive cardiac output Monitoring will be observed and analysed.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Non-invasive Blood Pressure and Cardiac Output Measurement by Using Applanation Tonometry

NCT02444104

Atrial Fibrillation Left Ventricular Failure Left Ventricular Impaired Function +1 more

UNKNOWN

DIGIPREDICT-Physio-DE

NCT05886569

Biomarkers

UNKNOWN NA

Mechanisms of Right Ventricular Adaptation in Patients With Heart Failure With Preserved Ejection Fraction

NCT04154657

Heart Failure, Diastolic

UNKNOWN NA

Study for the Evaluation of a Non-invasive Hemodynamic Measurement in Heart Failure Patients

NCT05441696

Congestive Heart Failure

ENROLLING_BY_INVITATION

Noninvasive Measurement of CO Using Impedance Cardiography in Patients With CHD

NCT02326649

Congenital Heart Disease

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure Hypertension, Pulmonary Hypertension Diabetic Nephropathies

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HFpEF

patients with heart failure with preserved ejection fraction

Endo-PAT

Intervention Type DEVICE

Analysis of endothelial function through pulse-amplitude-tonometry

NICOM

Intervention Type DEVICE

Non-invasive measurement of cardiac output

HFrEF

patients with heart failure with reduced ejection fraction

Endo-PAT

Intervention Type DEVICE

Analysis of endothelial function through pulse-amplitude-tonometry

AH

patients with hypertension

Endo-PAT

Intervention Type DEVICE

Analysis of endothelial function through pulse-amplitude-tonometry

NICOM

Intervention Type DEVICE

Non-invasive measurement of cardiac output

Nephropathy

patients with diabetic nephropathy

Endo-PAT

Intervention Type DEVICE

Analysis of endothelial function through pulse-amplitude-tonometry

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Endo-PAT

Analysis of endothelial function through pulse-amplitude-tonometry

Intervention Type DEVICE

NICOM

Non-invasive measurement of cardiac output

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinically stable for the last 4 weeks (not for HFrEF: 7 days)
* Signed consent form

HFpEF:

* Baseline-Echocardiography:
* hospitalization \<= 12 months with diagnosis heart failure and E/E' \> 8 or E' \< 8 cm/s or
* BNP \>= 100pg/ml or NT-proBNP \>= 300pg/ml in the last 6 months or
* LAVI \> 28 ml/m² and E/E' \> 8 or E' \< 8cm/s or PAPsys \> 40mmHg and E/E' \> 8 or E' \< 8 cm/s
* Possibility to take part in cardiac stress test
* Heart failure NYHA I-III
* Sinus rhythm
* Max. O2-uptake on exertion \< 20ml/kgBW/min

HFrEF

* HFrEF due to ischemic or non-ischemic reasons
* NYHA I-III
* Individually optimized and stable pharmacological therapy (including beta-blocker, ACE-Inhibitor, AT1-antagonist, aldosterone-antagonist)
* EF \<=45%, Simpson Biplan PH
* NICE-Classification 2013 I/II
* PAH \>= 25 mmHg
* Precapillary PAH: Wedge-pressure \<= 15 mmHg, CO normal or low
* Postcapillary PAH: Wedge-pressure \>= 15 mmHg, CO normal or low

Diabetic nephropathy:

* Diabetes mellitus Type 2 with oral or Insulin therapy and one or more of the following:
* Diabetic nephropathy has been diagnosed before (anamnesis)
* Macroalbuminuria: Urine Albumine/Creatinine-ratio \> 300mg/g Creatinine (\>34mg/mmol) in 2 out of 3 tests of Urine in the morning and GFR \<90ml/min/1.73m² (CKD-EPI)
* Microalbuminuria: 30-300mg/g Creatinine (\>=3.4 mg/mmol but \<34mg/mmol) tested as above and GFR \< 90 ml/min/1.73m² and diabetic retinopathy

AH:

* Hypertension diagnosed at least 6 months except structural heart disease: EF \> 55% and no sign of HFpEF
* No symptoms of coronary heart disease
* Possibility to take part in cardiac stress test
* Stable pharmacologic therapy of Hypertension for at least 4 weeks
* Systolic blood pressure \<140 mmHG during Screening

Exclusion Criteria

* Patient incapable of contracting
* Angina pectoris \> CCS II
* Coronary Intervention in the last 4 weeks or scheduled Intervention/Bypass
* Myocardial infarction in the last 3 months
* Stroke in the last 3 months
* Valvular heart disease \> II°
* Cardiomyopathy due to Infiltrate/hypertrophic obstruction (e.g. HOCM, Amyloidosis)
* Congenital complex heart disease
* Active myocarditis
* Significant lung disease
* Significant Cardiac dysrhythmia
* Scheduled changes in medication during time of study
* (Scheduled) heart transplant
* Cardiac resynchronisation therapy over the last three months
* ICD/Pacemaker-implant in the last 4 weeks
* Uncontrolled Hyper/Hypotension (\>180mmHg, \<95mmHg)
* Patient taking part in Rehabilitation program
* Diagnosed Malignant disease or disease with life expectancy \< 1 year
* Anemia with Hb\<10mg/dl
* Untreated significant thyroid disease

HFpEF, Hypertension and PH:

* Patient incapable of cardiac stress test (e.g. because of orthopedic Problems)
* Significant changes in cardiovascular Status over the two weeks of study
* Instable cardiopulmonary Status over the last four weeks

HFrEF:

* I.v. Treatment with inotropic drug or diuretic in the last 7 days before Screening
* Myocardial infarction in the last 4 weeks

Minimum Eligible Age

35 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No